News & Updates

People with idiopathic pulmonary fibrosis (IPF) who live near a major road tend to have a faster decrease in lung function, according to a study in Australia. Likewise, increased exposure to fine particulate matter (<2.5 μm, PM2.5) is associated with a higher rate of annual decline in diffusing capacity of the lungs for carbon monoxide (DLco).

In the phase III INSPIRE study, the novel, potent ALK tyrosine kinase inhibitor (TKI) iruplinalkib conferred a progression-free survival (PFS) benefit in patients with TKI-naïve, locally advanced, or metastatic ALK+ non-small-cell lung cancer (NSCLC).

Pretreatment level of serum carcinoembryonic antigen (CEA) is independently associated with overall and disease-free survival among patients with nonsmall cell lung cancer (NSCLC), reports a study. The same marker is also used for the prognosis of patients with the same pathologic stages.

In the merged analysis of the IMpower133 trial and IMbrella A open-label extension study, the combination of the PD-L1 inhibitor atezolizumab and a chemotherapy regimen comprising carboplatin and etoposide (CP/ET) demonstrated potential for survival benefit of up to 5 years in patients with extensive stage-small-cell lung cancer (ES-SCLC).

A systematic review and meta-analysis from Singapore demonstrates that parental smoking is not a strong risk factor for offspring eczema, food allergy, and food sensitization development.

Two studies presented at ERS 2023 demonstrated the potential of a continuous positive airway pressure (CPAP) machine to address cardiovascular (CV) risks in individuals with obstructive sleep apnoea (OSA).